Repros Announces Formation of Androxal(R) Clinical and Commercial Advisory Board

Repros Announces Formation of Androxal(R) Clinical and Commercial Advisory
Board

13 Leading KOL's Join Newly Formed Advisory Board

THE WOODLANDS, Texas, July 9, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) today announced the formation of an international,
multi-disciplinary, clinical advisory board to help maximize the commercial
opportunity for Androxal.

Management and the Board of Directors of Repros tasked Professor Mike Wyllie,
Ph.D., DSc, Director of Repros, and Ron Wiehle, Ph.D., V.P. of Research and
Development for Repros, to assemble a well-rounded and effective group of Key
Opinion Leaders (KOL's) to begin the multi-disciplinary patient and physician
education process that should have great utility for the Company independent
of the eventual Androxal commercial strategy.

It has become increasingly obvious that hypogonadism affects many facets of
daily living and impacts adversely on patients' quality of life.
Correspondingly, treatment has evolved and now involves not just andrologists
and urologists, but increasingly, endocrinologists. As with erectile
dysfunction, it is anticipated that with the arrival of orally effective
therapy, the management of hypogonadism will become the domain of primary care
physicians. Primarily the urology and andrology disciplines are to be
represented by KOL's at the inaugural advisory board to be held in October
2013, the members of which include:

  *Trinity Bivalacqua, M.D., Ph.D. – Associate Professor of Urology and
    Oncology, John Hopkins University
  *William Bremner, M.D., Ph.D. – Division of Metabolism, Endocrinology and
    Nutrition, University of Washington
  *John Dean, M.D. - Immediate past president of the International Society of
    Sexual Medicine (ISSM), Harley St, London, UK
  *Andre Guay, M.D. – Endocrinology, Diabetes and Metabolism, Lahey Clinic
    and Boston University
  *Lawrence Hakim, M.D. – Urologist, Cleveland Clinic and incoming president
    of Sexual Medicine Society of North America
  *Wayne Hellstrom, M.D., F.A.C.S. – Professor of Urology and Chief of
    Andrology, Tulane University, incoming President of ISSM
  *Edward Kim, Ph.D. – Professor at University of Tennessee Graduate School
    of Medicine
  *Larry Lipshultz, M.D. - Professor of Urology and Chief of the Division of
    Male Reproductive Medicine and Surgery at the Baylor College of Medicine
  *Andrew McCullough, M.D. - Professor of Urology/Division of Surgery, Albany
    Medical College: Urological Institute of North Eastern NY
  *Martin Miner, M.D. – Primary Care Physician with specialties in
    Hypogonadism, Erectile Dysfunction, Men's Health Center, Miriam Hospital
    and member of Princeton Guidelines on Cardiovascular Risk committee
  *David Rowland, Ph.D. – Professor of Psychology and Graduate Dean,
    Valparaiso University
  *Allen Seftel, M.D. – Head of Division of Urology, Cooper University
  *Myles Spar, M.D., M.P.H. – Internal Medicine, Director and Co-Director of
    Men's Clinic, Akasha Center

In parallel with the formation of this advisory board an additional advisory
board comprising primarily endocrinologists and primary care physicians is
being assembled over the next several weeks. In the past, the Company has used
Glenn Cunningham, M.D., Professor of Medicine and Molecular & Cellular
Biology, Baylor College of Medicine, Director, SLEH-BCM Diabetes Program and
Nelly Pitteloud, M.D., Professor of Medicine, Co-Chief, Endocrinology,
Diabetes and Metabolism Service, CHUV as endocrinology consultants.

It is anticipated that during the coming months while Androxal continues to
undergo its current Phase 3 clinical trials and regulatory review, a number of
advisory board meetings will convene. At these meetings, the KOL's will
discuss and develop programs to prepare the marketplace for the potential
launch of Androxal. A particular initial focus will be on programs designed to
facilitate discussions between patient and physician.

Mike Wyllie, Director of Repros, commented, "I am pleased with the enthusiasm
to participate and the quality and diversity of our advisory board. It is
important to prepare for the arrival of an effective oral therapy for the
treatment of secondary hypogonadism and provide the right support for patients
and providers."

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to raise additional needed capital on a
timely basis in order for it to continue to fund development of its Androxal^®
and Proellex^® programs, have success in the clinical development of its
technologies, the reliability of interim results to predict final study
outcomes, the uncertainty of regulatory review in the U.S. and other
jurisdictions, and such other risks which are identified in the Company's most
recent Annual Report on Form 10-K and in any subsequent quarterly reports on
Form 10-Q. These documents are available on request from Repros Therapeutics
or at www.sec.gov. Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.

CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer
        
         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931
         thoffmann@troutgroup.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.